ArticleFrontiers in immunology2017
Tumor-Derived Microvesicles Modulate Antigen Cross-Processing
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Enhanced mRNA vaccine combined with immune checkpoint blockade efficiently suppresses tumor growth and metastasis.Journal of nanobiotechnology · 2026Article
- Correlation Between Oxidative Stress and Immune Profiles During Immunotherapy in Metastatic Non-Oncogene-Addicted NSCLC Patients.Antioxidants (Basel, Switzerland) · 2026Article
- Exosomal non-coding RNAs: key molecules in the diagnosis and treatment of coronary artery disease.PeerJ · 2025Review
- Reactive oxygen species: Janus-faced molecules in the era of modern cancer therapy.Journal for immunotherapy of cancer · 2024Review
- DNA sensing of dendritic cells in cancer immunotherapy.Frontiers in molecular biosciences · 2024Review
- Comparison of immunotherapy mediated by apoptotic bodies, microvesicles and exosomes: apoptotic bodies' unique anti-inflammatory potential.Journal of translational medicine · 2023Review
- Research progress of tumor-derived extracellular vesicles in the treatment of malignant pleural effusion.Cancer medicine · 2023Review
- Proteomic characterization of extracellular vesicles released by third stage larvae of the zoonotic parasiteFrontiers in cellular and infection microbiology · 2023Article
- The potential applications of microparticles in the diagnosis, treatment, and prognosis of lung cancer.Journal of translational medicine · 2022Review
- Glycan-Lectin Interactions as Novel Immunosuppression Drivers in Glioblastoma.International journal of molecular sciences · 2022Review
- Microparticles: biogenesis, characteristics and intervention therapy for cancers in preclinical and clinical research.Journal of nanobiotechnology · 2022Review
- Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib.Frontiers in oncology · 2021Article
- Insights into the Role of Oxidative Stress in Ovarian Cancer.Oxidative medicine and cellular longevity · 2021Review
- Tumor-derived microparticles in tumor immunology and immunotherapy.European journal of immunology · 2020Review
- Tumor-Derived Extracellular Vesicles and the Immune System-Lessons From Immune-Competent Mouse-Tumor Models.Frontiers in immunology · 2020Review
- Tumor-derived extracellular vesicles: molecular parcels that enable regulation of the immune response in cancer.Journal of cell science · 2019Review
- Microvesicles and chemokines in tumor microenvironment: mediators of intercellular communications in tumor progression.Molecular cancer · 2019Review
- Roles of DNA repair enzyme OGG1 in innate immunity and its significance for lung cancer.Pharmacology & therapeutics · 2019Review
- Review
- Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells.Frontiers in immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendritic cells (DCs) are the only antigen-presenting cells able to prime
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.